Effect of Pioglitazone on Vascular Events in Post-stroke Cognitive Impairment: Post hoc Analysis of the IRIS Trial.

These data indicate that pioglitazone treatment may be more effective at reducing risk of recurrent stroke and MI in stroke patients with PSCI. Simple cognitive testing 2 to 3 months post-stroke may identify patients for whom treatment would be most beneficial.